XML 104 R71.htm IDEA: XBRL DOCUMENT v3.6.0.2
Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Alnylam Pharmaceuticals, Inc. (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2004
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Target
Program
Dec. 31, 2014
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Revenue earned   $ 160,349 $ 110,927 $ 38,470 $ 36,874 $ 51,571 $ 49,121 $ 120,428 $ 62,583 $ 346,620 $ 283,703 $ 214,161
Alnylam Pharmaceuticals, Inc. [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Upfront payment recorded as deferred revenue $ 5,000                      
Maximum amount of payments receivable per drug for milestone payments   3,400               3,400    
Maximum amount of payments receivable per drug for development milestones   1,100               1,100    
Maximum amount of payments receivable per drug for regulatory milestones   2,300               2,300    
Next prospective milestone   400               400    
Maximum amount of payments payable for development and regulatory milestones   3,400               3,400    
Number of therapeutic programs | Program                     4  
Number of therapeutic targets granted to Ionis | Target                     4  
Number of other unnamed therapeutic targets granted to Ionis | Target                     2  
Number of therapeutic targets granted by Ionis | Target                     4  
Cumulative payments received   $ 70,000               70,000    
Revenue earned                   $ 1,100 $ 1,300 $ 9,900